Tower Research Capital (TRC)’s Turnstone Biologics TSBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,741	Closed	-$1.7K	–	5639
2025 Q2	$1.7K	Sell	4,741 -20	-0.4%	-$7	﹤0.01%	4759
2025 Q1	$1.95K	Sell	4,761 -45	-0.9%	-$19	﹤0.01%	4620
2024 Q4	$2.39K	Sell	4,806 -170	-3%	-$84	﹤0.01%	4850
2024 Q3	$2.77K	Sell	4,976 -5,526	-53%	-$8.48K	﹤0.01%	4940
2024 Q2	$27.5K	Buy	10,502 +7,093	+208%	+$20.3K	﹤0.01%	3553
2024 Q1	$8.93K	Sell	3,409 -381	-10%	-$1.09K	﹤0.01%	3929
2023 Q4	$9.65K	Buy	3,790 +3,311	+691%	+$8.64K	﹤0.01%	4362
2023 Q3	$1.89K	Buy	+479	New	+$4.27K	﹤0.01%	5251

Tower Research Capital (TRC)'s TSBX Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 4,741 shares — an estimated $1.7K sold.

Tower Research Capital (TRC) first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $27.5K in Q2 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Tower Research Capital (TRC) reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 4,741 Turnstone Biologics shares in Q3 2025, an estimated $1.7K.
Tower Research Capital (TRC) first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
Tower Research Capital (TRC)'s Turnstone Biologics position peaked at $27.5K in Q2 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.